Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMIST-2: Simeprevir + Sofosbuvir in HCV Genotype 1 with Cirrhosis
NCT02114151Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Apr 2014
- Primary completion
- Jan 2015
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of simeprevir in hepatitis C virus infection, sponsored by Johnson & Johnson. Started Apr 2014; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT02114151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02114151.